<DOC>
	<DOCNO>NCT02728934</DOCNO>
	<brief_summary>The purpose study compare proportion patient infusion reaction Rheumatoid arthritis ( RA ) patient treat Golimumab Intravenous ( IV ) Infliximab .</brief_summary>
	<brief_title>Comparative Pragmatic Study Golimumab Intravenous ( IV ) ( Simponi Aria ) Versus Infliximab ( Remicade ) Rheumatoid Arthritis</brief_title>
	<detailed_description>This prospective , noninterventional ( treatment medication provide study ) , observational ( study investigators/ physician observe patient measure outcome ) , multicenter ( study conduct multiple site ) study Golimumab IV Infliximab RA patient . The study allow anticipate 2-year enrollment period 3-year study duration patient . No intervention give patient part study . This study conduct US , rheumatology-based clinical practice enroll adult RA patient meet entry criterion . The primary endpoint study proportion patient infusion reaction Week 52 . Patients enrol 1:1 ratio initiate treatment either Golimumab IV Infliximab . Patients ' safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient must male female 18 year age old study intend assess Golimumab intravenous ( IV ) Infliximab adult RA patient Patient must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Patient confirm diagnosis Rheumatoid arthritis ( RA ) medically eligible treatment Golimumab IV Infliximab accordance standard care ( example , screen tuberculosis [ TB ] , vaccination , etc . ) At time enrollment patient initiate treatment Golimumab IV Infliximab . The patient may may previously receive treatment biologic . Patients previous exposure subcutaneously administer Simponi may enroll study Patient must willing complete Patient report outcome ( PRO ) form study agree return complete form site receive infusion Golimumab IV Infliximab location remote study site Patient le 18 year age Patient pregnant planning pregnancy Patient currently enrol interventional study Patient receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 28 day , appropriate , plan first dose Golimumab IV Infliximab Patient previously receive Golimumab IV plan receive Golimumab IV study patient previously receive Infliximab plan receive Infliximab BI study . Patient previously receive BI plan receive BI Remicade study Patient condition , opinion investigator , participation would best interest patient ( example , compromise patient 's wellbeing ) could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Golimumab</keyword>
	<keyword>Infliximab</keyword>
</DOC>